The collaboration aims to develop miniaturised technology and use data to provide patients with better tools to self-manage the disease and offer healthcare professionals health data to better support and treat patients.
“This initiative combines Sanofi’s strength and knowledge in diabetes with Google’s leadership in technology and analytics to create a first-of-its-kind initiative with the potential to transform diabetes care,” said Sanofi CEO, Dr Olivier Brandicourt.
Through the partnership, the two companies will explore ways to collect, analyse and understand multiple sources of information impacting diabetes. It will bring together many of the previously siloed pieces of diabetes management and enable new kinds of interventions.
“With new technologies emerging to provide a more continuous and real-time view of a patient’s health, we can see the promise for more proactive and effective ways to control diabetes,” said CEO of the life sciences team at Google, Andy Conrad.
“Together with Sanofi, we believe diabetes management can be simpler and more convenient, which may help patients achieve an improved quality of life,” continued Conrad.
Since the creation of its life sciences division, Google has expanded its footprint in the healthcare technology space through collaborations with key partners. In August, Google teamed up with leading continuous glucose-monitoring (CGM) company, DexCom to develop smaller, better devices for people with diabetes.
Last year Google joined forces with pharmaceutical company, Novartis, to develop a smart contact lens that will help people with diabetes monitor their blood-sugar levels continuously.
In June 2015, the Life Sciences Group announced a new health-tracking wristband that can be prescribed to patients or used in clinical trials to provide researchers and doctors with real-time data on how patients are progressing.
“Technology, sensors, analytics, and digital solutions will revolutionise how blood sugars are managed, which will deliver improved quality of life, lowering the risk of complications and reducing the costs and barriers associated with diabetes care,” said President and CEO of the Joslin Diabetes Center, which is a partner to the collaboration, John L. Brooks, III.